# Eclipse Bioinnovations

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eclipse-bioinnovations

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.eclipsebio.com
- Total disclosed funding: $12M
- Latest round: Series A (Aug 27, 2021)
- Investors on record: 4

## About

Based in California, US, and founded in 2017 by its CEO, Peter Chu and co-founder, Alexander Shishkin, Eclipse Bioinnovations, Inc. operates as an RNA genomics company that provides products and services to academic and industry customers. In September 2021, Eclipse Bioinnovations, Inc. raised USD 11.95 million in series A funding co-led by new investors Alexandria Venture Investments and iGlobe Partners, with participation from other new investors Phoenix Venture Partners and Photon Ventures.

Eclipse Bioinnovations, Inc. offers an end-to-end RNA genomics product and service that includes RBP-eCLIP Kit is a preparation method to identify RNA-binding proteins, m6A-eCLIP Kit allows researchers to map m6A RNA modification states, FLI-Seq Kit removes undesired genomic DNA, eCLIP Antibody Validation Kit validates antibodies for immunoprecipitation in eCLIP buffers, and 5' & 3' End-Seq Kits enable the user to detect either 5’ or 3’ transcript ends genome-wide with single-nucleotide resolution. In addition, the company provides custom RNA genomics services.

The company will use the series A funding to expand its RNA genomics technologies and products.

## Funding rounds

- Series A, Aug 27, 2021, $12M — Alexandria Venture Investments, iGlobe Partners, Phoenix Venture Partners, Photon Ventures

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- iGlobe Partners (https://capitalatlas.ai/funds/iglobe-partners) — Series A
- Phoenix Venture Partners — Series A
- Photon Ventures — Series A